Drug · CHEMBL1682
SORBITOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SORBITOL. Drugs and targets, record CHEMBL1682. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1682
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
7B5697N, D-glucitol, D-glucitol syrup, D-sorbitol, E 420, E-420(i), FEMA NO. 3029, Glucitol, d-, Ins no.420(i), Ins-420(i), Isomalt impurity, sorbitol-, NSC-25944, Neosorb p 60w, Sorbitol (e420), Sorbitol solutions
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Charcot-Marie-Tooth disease type 1A | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0007309 |
| constipation disorder | Approval | ATC and TTD | 4 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002203 |
| gastric cancer | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| gastroesophageal junction adenocarcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0003219 |
Source Open Targets
Trials12
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02579759 | Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) | Phase 3 | 323 | 2020-02-27 | D-sorbitol | Its name | ClinicalTrials.gov |
| NCT01401257 | Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A | Phase 2 | 80 | 2017-02-16 | sorbitol | Its name | ClinicalTrials.gov |
| NCT02634073 | A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers | Phase 4 | 16 | 2017-05-15 | sorbitol | Its name | ClinicalTrials.gov |
| NCT04762758 | Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients | Phase 3 | 350 | d-sorbitol | Its name | ClinicalTrials.gov | |
| NCT01474499 | A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation | Phase 3 | 300 | sorbitol | Its name | ClinicalTrials.gov | |
| NCT03023540 | Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A | Phase 3 | 187 | D-sorbitol | Its name | ClinicalTrials.gov | |
| NCT03764085 | Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis. | Phase 4 | 180 | sorbitol | Its name | ClinicalTrials.gov | |
| NCT03771170 | Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis | Phase 4 | 180 | sorbitol | Its name | ClinicalTrials.gov | |
| NCT03824457 | Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia | Phase 4 | 150 | rheosorbilact®, sorbitol | Its name | ClinicalTrials.gov | |
| NCT06826079 | Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer | Phase 2 | 86 | sorbitol | Its name | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials6
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1682
GET https://conductscience.org/api/drugs/v1/CHEMBL1682/targets